{"id":"NCT01180036","sponsor":"Mayo Clinic","briefTitle":"MEmbranous Nephropathy Trial Of Rituximab","officialTitle":"\"A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)\"","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-11","primaryCompletion":"2017-10-01","completion":"2017-10-01","firstPosted":"2010-08-11","resultsPosted":"2019-04-30","lastUpdate":"2019-04-30"},"enrollment":130,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Membranous Nephropathy"],"interventions":[{"type":"DRUG","name":"Rituximab","otherNames":["Rituxan, MabThera"]},{"type":"DRUG","name":"Cyclosporine","otherNames":["Sandimmune"]}],"arms":[{"label":"Rituximab Treatment Arm","type":"ACTIVE_COMPARATOR"},{"label":"Cyclosporine Treatment Arm","type":"ACTIVE_COMPARATOR"}],"summary":"The primary outcome of this study is to determine whether or not the B cell targeting with Rituximab is non-inferior or more effective than Cyclosporine in inducing long term remission of proteinuria.","primaryOutcome":{"measure":"Remission Status","timeFrame":"24 months after randomization","effectByArm":[{"arm":"Rituximab Treatment Arm","deltaMin":39,"sd":null},{"arm":"Cyclosporine Treatment Arm","deltaMin":13,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":21,"countries":["United States","Canada"]},"refs":{"pmids":["34778952","32231244","31269364","26087670"],"seeAlso":["https://www.mayo.edu/research/clinical-trials"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":65},"commonTop":["General","Infections","Musculoskeletal","Nervous system","Gastrointestinal"]}}